Treatment of patients with acute schizophrenia using paliperidone extended-release tablets: A 6-week placebo-controlled study

被引：0
|
作者：
Kane, JM [1 ]
Kramer, M [1 ]
Ford, L [1 ]
Gassmann-Mayer, C [1 ]
Lim, P [1 ]
Eerdekens, M [1 ]
机构：
[1] Zucker Hillside Hosp, Dept Psychiat, New York, NY USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2005年 / 30卷
关键词：
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
引用
收藏
页码：S191 / S192
页数：2
相关论文
共 50 条
  • [41] Delaying symptom recurrence in patients with schizophrenia treated with paliperidone extended-release tablets
    Kramer, M.
    Kushner, S.
    Vijapurkar, U.
    Lim, P.
    Eerdekens, M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 : S387 - S387
  • [42] Efficacy of paliperidone extended-release tablets in patients with schizophrenia and predominant negative symptoms
    Dirks, B.
    Eerdekens, M.
    Turkoz, I.
    Alberio, R.
    Gharabawi, G.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S162 - S162
  • [43] Randomized, Double-Blind, Placebo-Controlled Study of Paliperidone Extended-Release and Quetiapine in Inpatients With Recently Exacerbated Schizophrenia
    Canuso, Carla M.
    Dirks, Bryan
    Carothers, Jennifer
    Kosik-Gonzalez, Colette
    Bossie, Cynthia A.
    Zhu, Young
    Damaraju, C. V.
    Kalali, Amir H.
    Mahmoud, Ramy
    AMERICAN JOURNAL OF PSYCHIATRY, 2009, 166 (06): : 691 - 701
  • [44] Paliperidone extended-release tablets in Chinese patients with schizophrenia: meta-analysis of randomized controlled trials
    Cai, Shangli
    Lu, Huafei
    Bai, Zhihua
    Wu, Renrong
    Zhao, Jingping
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2015, 11 : 1817 - 1834
  • [45] Safety and Efficacy of Paliperidone Extended-Release in Acute and Maintenance Treatment of Schizophrenia
    Spina, Edoardo
    Crupi, Rosalia
    JOURNAL OF CENTRAL NERVOUS SYSTEM DISEASE, 2011, 3 : 27 - 41
  • [46] A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia (vol 22, pg 299, 2007)
    Luthringer, R.
    Staner, L.
    Noel, N.
    Muzet, M.
    Gassmann-Mayer, C.
    Talluri, K.
    Cleton, A.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2007, 22 (06) : 387 - 387
  • [47] The Efficacy and Tolerability of Once-Daily Extended Release Quetiapine Fumarate in Hospitalized Patients with Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Study
    Lindenmayer, Jean-Pierre
    Brown, David
    Liu, Sherry
    Brecher, Martin
    Meulien, Didier
    PSYCHOPHARMACOLOGY BULLETIN, 2008, 41 (03) : 11 - 35
  • [48] A Failed 6-Week, Randomized, Double-Blind, Placebo-Controlled Study of Once-Daily Extended Release Quetiapine Fumarate in Patients with Acute Schizophrenia: Lessons Learned
    Cutler, Andrew J.
    Tram Tran-Johnson
    Kalali, Amir
    Astrom, Mikael
    Brecher, Martin
    Meulien, Didier
    PSYCHOPHARMACOLOGY BULLETIN, 2010, 43 (04) : 37 - 69
  • [49] Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study
    Goldman, Robert
    Loebel, Antony
    Cucchiaro, Josephine
    Deng, Ling
    Findling, Robert L.
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2017, 27 (06) : 516 - 525
  • [50] Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6-week, randomized, double-blind, placebo-controlled study
    Ishigooka, Jun
    Iwashita, Shuichi
    Tadori, Yoshihiro
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2018, 72 (09) : 692 - 700
12345